Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Mohamed Ali, Sara A R, Sara A.R., Ayman Al Hendy
Expert review of clinical pharmacology · 2021 · vol. 14(4) , pp. 427–437 · doi:10.1080/17512433.2021.1900726 · PMID:33682578 · W3135636650
review OA: green CC0 ⤵ 4 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Elagolix, an oral GnRH antagonist, is approved for treating heavy menstrual bleeding in premenopausal women with uterine fibroids, offering a new noninvasive therapeutic option.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Uterine fibroids (UFs) are the most common benign tumor arising from myometrium of reproductive age women, with significant financial burden estimated in hundreds of billions of dollars. Unfortunately, there are limitations in available long-term treatment options. Thus, there is a large unmet need in the UF space for noninvasive therapeutics. AREAS COVERED: Authors reviewed the literature available for elagolix; an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) antagonist recently approved by the US Food and Drug Administration (FDA) in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with UFs in premenopausal women. EXPERT OPINION: The utility of new-generation oral GnRH-antagonists, such as elagolix, relugolix and linzagolix, is offering a new potential opportunity for the future therapy of UFs: elagolix has been the most studied drug of this class for treating benign gynecological diseases, including endometriosis and UFs, for which it has been US FDA-approved in 2018 and 2020, respectively.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Hydrocarbons, Fluorinated Menorrhagia Pyrimidines Animals Drug Combinations Estradiol Estradiol Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Hydrocarbons, Fluorinated Hydrocarbons, Fluorinated Leiomyoma Leiomyoma Leiomyoma Menorrhagia Menorrhagia Norethindrone Norethindrone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:24:49.034193+00:00
License: CC0 · commercial use OK